Influence of short‐term dexamethasone on the efficacy of
            177
            Lu‐PSMA‐617 in patients with metastatic castration‐resistant prostate cancer

Chakravarty D, Gao J, Phillips SM, Kundra R, Zhang H, Wang J, Rudolph JE, Yaeger R, Soumerai T, Nissan MH, Chang MT, Chandarlapaty S, Traina TA, Paik PK, Ho AL, Hantash FM, Grupe A, Baxi SS, Callahan MK, Snyder A, Chi P, Danila D, Gounder M, Harding JJ, Hellmann MD, Iyer G, Janjigian Y, Kaley T, Levine DA, Lowery M, Omuro A, Postow MA, Rathkopf D, Shoushtari AN, Shukla N, Voss M, Paraiso E, Zehir A, Berger MF, Taylor BS, Saltz LB, Riely GJ, Ladanyi M, Hyman DM, Baselga J, Sabbatini P, Solit DB, Schultz N. OncoKB: a precision oncology knowledge base. JCO Precis Oncol 2017 Jul;2017 https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/28890946/ Newton Y, Novak AM, Swatloski T, McColl DC, Chopra S, Graim K, Weinstein AS, Baertsch R, Salama SR, Ellrott K, Chopra M, Goldstein TC, Haussler D, Morozova O, Stuart JM. TumorMap: exploring the molecular similarities of cancer samples in an interactive portal. Cancer Res 2017 Nov 1;77(21):e111-e114 https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/29092953/ Seyednasrollah F, Koestler DC, Wang T, Piccolo SR, Vega R, Greiner R, Fuchs C, Gofer E, Kumar L, Wolfinger RD, Winner KK, Bare C, Neto EC, Yu T, Shen L, Abdallah K, Norman T, Stolovitzky G, Soule HR, Sweeney CJ, Ryan CJ, Scher HI, Sartor O, Elo LL, Zhou FL, Guinney J, Costello JC, and Prostate Cancer DREAM Challenge Community. A DREAM challenge to build prediction models for short-term discontinuation of docetaxel in metastatic castration-resistant prostate cancer. JCO Clin Cancer Inform 2017 Aug 4;(1):1-15 http://ascopubs.org/doi/abs/10.1200/CCI.17.00018

Download Full-text

Castration-Resistant Prostate Cancer Outcome Prediction Using Phased Long Short-Term Memory with Irregularly Sampled Serial Data

Applied Sciences ◽

10.3390/app10062000 ◽

2020 ◽

Vol 10 (6) ◽

pp. 2000 ◽

Cited By ~ 1

Author(s):

Jihwan Park ◽

Mi Jung Rho ◽

Hyong Woo Moon ◽

Ji Youl Lee

Keyword(s):

Prostate Cancer ◽

Decision Making ◽

Outcome Prediction ◽

Short Term Memory ◽

Castration Resistant Prostate Cancer ◽

Short Term ◽

Term Memory ◽

Castration Resistant ◽

Serial Data ◽

Long Short Term Memory

It is particularly desirable to predict castration-resistant prostate cancer (CRPC) in prostate cancer (PCa) patients, and this study aims to predict patients’ likely outcomes to support physicians’ decision-making. Serial data is collected from 1592 PCa patients, and a phased long short-term memory (phased-LSTM) model with a special module called a “time-gate” is used to process the irregularly sampled data sets. A synthetic minority oversampling technique is used to overcome the data imbalance between two patient groups: those with and without CRPC treatment. The phased-LSTM model is able to predict the CRPC outcome with an accuracy of 88.6% (precision-recall: 91.6%) using 120 days of data or 94.8% (precision-recall: 96.9%) using 360 days of data. The validation loss converged slowly with 120 days of data and quickly with 360 days of data. In both cases, the prediction model takes four epochs to build. The overall CPRC outcome prediction model using irregularly sampled serial medical data is accurate and can be used to support physicians’ decision-making, which saves time compared to cumbersome serial data reviews. This study can be extended to realize clinically meaningful prediction models.

Download Full-text